someone [18:30 60 minutes following administration of a partial reversing dose (i.e., 1 mcg/kg). a Effects may persist for several hours following administration of a full reversing dose (i.e., 1 mg/70 kg). a Distribution Extent Rapidly distributed following IV administration, with 80% of brain opiate receptors blocked within 5 minutes of administration. a Distributed into milk in rats; not known whether distributed into human milk. a Plasma Protein Binding 45%. a Elimination Metabolism Metabolized in the liver, primarily by glucuronide conjugation to nalmefene glucuronide, an inactive metabolite. a Elimination Route Excreted principally in urine, mainly as metabolites, and in feces (17%). a Half-life Biphasic; terminal half-life is approximately 10.8 hours. a Special Populations In patients with end-stage renal disease, clearance of nalmefene is reduced by 25 27% compared with that in healthy adults and half-life is increased to around 26.1 hours. a In patients with hepatic impairment, clearance of nalmefene is reduced by 28.3%. a In geriatric patients, no substantial differences in clearance, steady-state volume of distribution, or half-life relative to younger adults. a Stability Storage Parenteral Injection 15 30 ºC. a Actions A long-acting opiate antagonist. 1 a Antagonizes the effects of opiates (e.g., respiratory depression, sedation, hypotension). a In patients who have not recently received opiates, nalmefene exerts no pharmacologic effect. a Does not produce tolerance, physical dependence, or have abuse potential. a May precipitate acute withdrawal in individuals physically dependent on opiates. a Advice to Patients Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs as well as any concomitant illnesses. a Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed. a Importance of informing patients of other important precautionary information. (See Cautions.) Preparations Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details. Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations. Nalmefene Hydrochloride Routes Dosage Forms Strengths Brand Names Manufacturer Parenteral Injection 100 mcg (of nalmefene) per mL Revex Baxter 1 mg (of nalmefene) per mL Revex Baxter AHFS DI Essentials. Copyright 2017, Selected Revisions February 1, 2008. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814. References 1. Ohmeda Pharmaceuticals. Revex (nalmefene hydrochloride) injection prescribing information. Library Corner, NJ; 1996 Mar. a. Baxter Healthcare Corporation. Revex (nalmefene hydrochloride) injection prescribing information. Decatur, IL; 2006 May. b. Baxter Healthcare Corporation, Round Lake; IL: Personal communication. Next Interactions Print this page Add to My Med List More about nalmefene Side Effects During Pregnancy Drug Interactions Support Group 0 Reviews Add your own review/rating Drug class: antidotes Professional resources Other brands: Revex Related treatment guides Opioid Overdose Reversal of Opioid Sedation] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Availability Discontinued B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Drug Class Antidotes Related Drugs Reversal of Opioid Sedation naloxone , Evzio , Narcan Nasal Spray , Narcan Injection , nalmefene , Revex , More... Opioid Overdose naloxone , Evzio , Narcan Nasal Spray , Narcan Injection , nalmefene , Revex , More... Nalmefene Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! weak spot
induced Nalmefene Hydrochloride most dear
EmoticonEmoticon